These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8032956)

  • 1. 5-Fluorouracil pharmacokinetics in patients with metastatic colorectal carcinoma after high-dose leucovorin.
    Stein TA; Burns GP; Bailey B; Citron ML
    Cancer Invest; 1994; 12(4):375-8. PubMed ID: 8032956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group.
    Petrelli N; Douglass HO; Herrera L; Russell D; Stablein DM; Bruckner HW; Mayer RJ; Schinella R; Green MD; Muggia FM
    J Clin Oncol; 1989 Oct; 7(10):1419-26. PubMed ID: 2674331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid.
    Joulia JM; Pinguet F; Ychou M; Duffour J; Astre C; Bressolle F
    Eur J Cancer; 1999 Feb; 35(2):296-301. PubMed ID: 10448274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
    Schilsky RL; Hohneker J; Ratain MJ; Janisch L; Smetzer L; Lucas VS; Khor SP; Diasio R; Von Hoff DD; Burris HA
    J Clin Oncol; 1998 Apr; 16(4):1450-7. PubMed ID: 9552051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil.
    Kerr DJ; Ledermann JA; McArdle CS; Buckels J; Neoptolemos J; Seymour M; Doughty J; Budden J; Taylor I
    J Clin Oncol; 1995 Dec; 13(12):2968-72. PubMed ID: 8523062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.
    Borner MM; Schoffski P; de Wit R; Caponigro F; Comella G; Sulkes A; Greim G; Peters GJ; van der Born K; Wanders J; de Boer RF; Martin C; Fumoleau P
    Eur J Cancer; 2002 Feb; 38(3):349-58. PubMed ID: 11818199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
    Ho YF; Lu WC; Chen RR; Cheng AL; Yeh KH
    Anticancer Drugs; 2011 Mar; 22(3):290-8. PubMed ID: 21150775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients.
    Falcone A; Danesi R; Dargenio F; Pfanner E; Brunetti I; Del Tacca M; Nethersell AB; Conte PF
    J Clin Oncol; 1996 Mar; 14(3):729-36. PubMed ID: 8622018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose and time dependencies of 5-fluorouracil pharmacokinetics.
    Terret C; Erdociain E; Guimbaud R; Boisdron-Celle M; McLeod HL; Féty-Deporte R; Lafont T; Gamelin E; Bugat R; Canal P; Chatelut E
    Clin Pharmacol Ther; 2000 Sep; 68(3):270-9. PubMed ID: 11014408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
    Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
    Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.
    Harte RJ; Matthews JC; O'Reilly SM; Tilsley DW; Osman S; Brown G; Luthra SJ; Brady F; Jones T; Price PM
    J Clin Oncol; 1999 May; 17(5):1580-8. PubMed ID: 10334547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer.
    Cho HK; Lee ES; Lee JW; Park JK; Kang JH; Lee KS; Shim CK; Chung SJ; Kim DD; Kuh HJ
    J Cancer Res Clin Oncol; 2006 May; 132(5):320-6. PubMed ID: 16395593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of the administration of amifostine on the pharmacokinetics of 5-fluorouracil in patients with metastatic colorectal carcinoma.
    Martens-Lobenhoffer J; Fuhlroth J; Ridwelski K
    Int J Clin Pharmacol Ther; 2000 Jan; 38(1):41-4. PubMed ID: 10667836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dose-intensive regimen of 5-fluorouracil for the treatment of metastatic colorectal carcinoma.
    Poplin EA; Kraut M; Baker L; Brodfuehrer J; Vaitkevicius V
    Cancer; 1991 Jan; 67(2):367-71. PubMed ID: 1985732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
    Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
    Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients.
    Gamelin E; Boisdron-Celle M; Delva R; Regimbeau C; Cailleux PE; Alleaume C; Maillet ML; Goudier MJ; Sire M; Person-Joly MC; Maigre M; Maillart P; Fety R; Burtin P; Lortholary A; Dumesnil Y; Picon L; Geslin J; Gesta P; Danquechin-Dorval E; Larra F; Robert J
    J Clin Oncol; 1998 Apr; 16(4):1470-8. PubMed ID: 9552054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma.
    Peters GJ; Lankelma J; Kok RM; Noordhuis P; van Groeningen CJ; van der Wilt CL; Meyer S; Pinedo HM
    Cancer Chemother Pharmacol; 1993; 31(4):269-76. PubMed ID: 8422689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.
    Poon MA; O'Connell MJ; Moertel CG; Wieand HS; Cullinan SA; Everson LK; Krook JE; Mailliard JA; Laurie JA; Tschetter LK
    J Clin Oncol; 1989 Oct; 7(10):1407-18. PubMed ID: 2476530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-FU split dose; a phase I/II and pharmacokinetic study of a different schedule of the Nordic regimen in advanced colorectal carcinoma.
    Berglund A; Carlsson G; Gustavsson B; Frödin JE; Ragnhammar P; Glimelius B
    Anticancer Res; 2003; 23(2C):1789-94. PubMed ID: 12820460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group.
    Valone FH; Friedman MA; Wittlinger PS; Drakes T; Eisenberg PD; Malec M; Hannigan JF; Brown BW
    J Clin Oncol; 1989 Oct; 7(10):1427-36. PubMed ID: 2789272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.